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Abstract
Introduction: It has been shown that more than 50% of people with a chronic disease, including osteoporosis, discontinue treatment
during its first year. This problem increases with the time of observation.
The aim of this study was to assess alendronate compliance over a period of 6 or 18 months in clinical practice of postmenopausal osteopo-
rosis.
Material and methods: Using a retrospective study of clinical histories (357) obtained in our Outpatient Clinic, as well as telephone
interviews with patients, the compliance with alendronate therapy in postmenopausal patients was assessed.
Results: After 1.5 years on observation 20.4% of patients, and after 0.5 years 8.5% of patients, discontinued their treatment as a result of
intolerance (especially side effects on the gastrointestinal tract) (47.8%), health problems unrelated to osteoporosis (8.7%), inconvenience
of the daily regimen (13.1%), costs (4.3%), and improvement of clinical condition (26.1%). It is worth mentioning that in both periods of
observation (1.5 and 0.5 years) almost the same percentage of patient discontinued visits at our Outpatient Clinic (15.6% and 14.4%,
respectively). Telephone interviews with patients who stopped attending the Outpatient Clinic at the Regional Centre of Menopause and
Osteoporosis revealed that more than 50% of them discontinued the treatment.
Conclusions: Not all patients treated with alendronate are compliant. Osteoporosis is a chronic disease, which needs long clinical observa-
tion and constant adherence to medication. Effective communication between doctor and patient, and follow-up visits that are more
frequent would greatly improve the adherence to osteoporosis treatment modalities. Compliant patients achieved increases in bone mass
density with simultaneous fracture risk reduction. (Pol J Endocrinol 2009; 60 (2): 76–81)
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Streszczenie
Wstęp: Wykazano, że ponad 50% pacjentów leczonych z powodu chorób przewlekłych, w tym osteoporozy, przerywa terapię w ciągu
pierwszego roku jej stosowania. Problem ten narasta z czasem trwania obserwacji.
Celem pracy była ocena stopnia przestrzegania zaleceń terapii przewlekłej przez pacjentki leczone z powodu osteoporozy.
Materiał i metody: Ocenie poddano 357 losowo wybranych historii chorób osób, które pierwszy raz były konsultowane w Regionalnym
Ośrodku Osteoporozy i Menopauzy w łodzi w roku 2003 i 2004. Analizą objęto pacjentów leczonych preparatem alendronian 10. Wzięto
pod uwagę czas trwania obserwacji, zakres kontynuacji, przyczynę przerwania stosowanego leczenia.
Wyniki: W okresie 18 miesięcznej obserwacji leczenie przerwało 20,4% pacjentów, natomiast w okresie obserwacji 6 miesięcznej 8,5%.
Przyczyny przerwania terapii alendronianem 10 były następujące: brak tolerancji ze strony przewodu pokarmowego (47,8%), współist-
niejące choroby (8,7%), uciążliwość przyjmowania leku w terapii codziennej (13,1%), cena leku (4,3%) oraz poprawa kliniczna (26,1%).
Zarówno w jednym, jak i drugim okresie obserwacji stwierdzono porównywalną grupę pacjentów, którzy nie zgłosili się ponownie na
konsultacje lub z którymi nie ma kontaktu od co najmniej pół roku do roku (odpowiednio: 15,6% dla obserwacji 1½ rocznej; 14,4% dla
obserwacji ½ rocznej). Po weryfikacji telefonicznej stwierdzono, że ponad połowa pacjentów nie zgłaszających się nie kontynuuje zaleco-
nego leczenia.
Wnioski: Nie wszyscy pacjenci leczeni z powodu osteoporozy kontynuują zalecone leczenie. Im dłużej trwa leczenie tym większy jest
odsetek pacjentów przerywających terapię. Choroba przewlekła wymaga wypracowania zasad współpracy pomiędzy prowadzącym
lekarzem a pacjentem, której celem jest lepsze przestrzeganie zaleconych zasad postępowania terapeutycznego co może odnieść wymier-
ny skutek w postaci poprawy stanu klinicznego. (Endokrynol Pol 2009; 60 (2): 76–81)
Słowa kluczowe: przestrzeganie zaleceń lekarskich, osteoporoza, alendronian 10, przyczyny przerwania terapii
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Introduction
Osteoporosis is a major public health problem in many
countries, including Poland [1]. Currently, the availa-
ble treatment options increase bone mineral density
(BMD) and decrease fracture risk [2–7]. In order to ob-
tain benefit from their medication, patients should ma-
intain optimal compliance and persist with their oste-
oporosis therapy [8, 9]. The definitions of these three
words: compliance, persistence and adherence, are pre-
sent in many papers [10–13]. The term adherence is used
to imply both compliance (medication intake regularity)
and persistence (medical therapy duration).
It has been shown that more than 50% of people
with chronic disease, including osteoporosis, disconti-
nue treatment during its first year [14]. This problem
increases with the time of observation. It has been ob-
served that 13% of women who were prescribed oral
daily alendronate did not even start the treatment, and
20% of patients discontinued the therapy during the
first 4 months [15, 16]. This problem does not depend
on the form of treatment [11].
Longitudinal, retrospective analyses in large data-
bases illustrate that adherence to osteoporosis therapies
is poor. Boguzzi and colleagues [17] presented the re-
sults of a study involving a cohort of 10,566 women,
showing that adherence during one year was higher
with two bisphosphonates: alendronate (60.7%) and ri-
sedronate (58.4%), and lower with raloxifene (53.9%).
Persistence, however, was poor for all the agents (alen-
dronate 23%, risedronate 19.4%, and raloxifene 16.2%).
A somewhat higher range for persistence at 12 months
has been presented in other papers [18]. In three exa-
mined countries, the compliance was as follows: 32%
in the United States, 40% in the United Kingdom, and
44% in France. Women on daily alendronate persisted
with treatment for 185 days in the United States,
208 days in the United Kingdom, and 155 days in Fran-
ce [18]. The persistence curves for osteoporosis medica-
tions showed a rapid decrease within the first 3 months
of therapy [15–17]. Similarly, a retrospective study of
postmenopausal women who used alendronate, calci-
tonin, HRT, raloxifene, or risedronate showed complian-
ce below 66% during a 60-day period [19]. Adherence
to medication recommendations in osteoporosis is very
important because it has been shown that compliance
below 66% with drug treatment results in suboptimal
improvement in bone mineral density [20].
The aim of the present study was an assessment of
alendronate compliance (administered daily) during the
treatment of osteoporosis within the period of 6 and
18 months in the clinical practice of patients from the
Outpatient Clinic at the Regional Centre of Menopause
and Osteoporosis in Łódź.
Material and methods
Three hundred and fifty-seven (357) randomly se-
lected case records of persons who were for the first
time consulted at the Regional Centre of Menopause
and Osteoporosis during the years 2003 and 2004 were
submitted for evaluation. The analysis comprised pa-
tients treated with an agent from the bisphosphonate
group (alendronate 10, administered once daily). The
follow up period, the scope of continuation, and the cause
of treatment withdrawal were taken into account.
Results
The reasons for the patient’s first visit at the Osteopo-
rosis Outpatient Clinic — own experience: 1. A patient
untreated before (in our material, following randomly
selected case records in 2003 — 69%; in 2004 — 77%):
suspected diagnosis of osteoporosis in radiological stu-
dies of bones, identified bone fracture, prompting the
diagnosis of osteoporosis, abnormal bone density re-
sults in screening tests. 2. A patient treated before (in
our material, on the basis of randomly selected case re-
cords 2003 — 31%; 2004 — 23%): other examinations
performed before: forearm, spine DXA, or sonographic
imaging, which prompted the onset of treatment,
a change of osteoporosis therapy centre due to the ob-
served lack of improvement, patient’s referral to a spe-
cialist unit following the failed attempt of osteoporosis
treatment by glucocorticosteroids.
Following our own observations, patients who at-
tend the clinic for the first time are prompted by: a con-
scious intention to have BMD evaluated, especially in
the case of post-menopausal patients who are referred
for secondary osteoporosis diagnostics or BMD prior to
steroid therapy administration.
According to the evaluated case records, it was fo-
und that, out of the group of patients attending the cli-
nic for the first time, approximately 62% required con-
tinuation of previously administered therapy. The re-
maining patients required verification of the earlier dia-
gnosis, obtained from X-ray picture or peripheral
densitometry.
It appears from the analysis that during the 1.5-year
observation period of the patients treated with alen-
dronate 10, the therapy was discontinued by 20.4% of
the patients (Table I), while during a 6-month obse-
rvation period, 8.5% of the patients discontinued tre-
atment (Table II).
While evaluating the reasons for treatment discon-
tinuation, it was determined that, most often, it resul-
ted from poor gastric tolerance of the agent (47.8%),
followed by concomitant diseases (8.7%), inconvenien-
ces associated with drug intake by daily dose regimen
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(13.1%), drug costs (4.3%), and clinical improvement rate
(26.1%) (Table III).
It should be underlined that after both the first and
the second observation periods, a comparative group
of patients was found, who did not turn up for follow
up visits or with whom all contact had been lost for at
least half a year (15.6% for the 18-month observation
and 14.4% for the 6-month observation, respectively).
Following telephone verification, it turned out that more
than half of the non-attending patients discontinued
the recommended treatment (Tables I and II).
It appears from our observations that 63% of the
patients during the follow up period used one agent,
while 37% of the subjects were treated with several com-
bined medications, which was associated with intole-
rance to the drug, inconvenience of daily drug intake,
or with financial aspects (Table IV).
Discussion
Osteoporosis is a chronic disease, which needs long cli-
nical observation and constant adherence to medica-
tion.
In the present study, alendronate compliance in the
clinical practice of osteoporosis was time dependent
and, overall, moderate. The analysis of clinical records
has shown that 62% of patients with osteoporosis had
been treated before and, after our initial consultation,
the treatment was continued. In the remaining group,
after our initial consultation, the treatment was stop-
ped. The main reason for therapy discontinuation was
the introduction of a new treatment before initial con-
sultation with the patient and before central densito-
metry was done, according to the resolutions of the
Position Development Conferences for the purpose of
establishing standards and guidelines for indications,
acquisition, and interpretation of bone density tests [21,
22], which is also obligatory in our country [23, 24].
The data from our study have shown that, after
18 months of observation 20.4% of patients, and after
Table I. Based on the records of 137 patients admitted
for the first time in 2003, anti-resorptive treatment was
applied in 72 cases, where alendronate was administered
in 64 in doses of 10 mg/d.
Tabela I. Analiza dokumentacji medycznej 137 pacjentów
hospitalizowanych po raz pierwszy w 2003 roku wykazała,
że leki przeciwresorpcyjne zalecono u 72 osób, przy czym 64
osoby otrzymały alendronian w dawce 10 mg/d
Administered Number Compliance
treatment  of subjects
Alendronate 10 64 Yes 41 (64%)
No 13 (20.4%)
Lost contact for 10 (15.6%)
the last year
Table II. Based on the records of 204 patients admitted for
the first time in 2004, anti-resorptive treatment was applied
in 125 cases, where alendronate was administered in 118 in
doses of 10 mg/d.
Tabela II. Analiza dokumentacji medycznej 204 pacjentów
hospitalizowanych po raz pierwszy w 2004 roku wykazała,
że leki przeciwresorpcyjne zalecono u 125 osób, przy czym
118 osób otrzymało alendronian w dawce 10 mg/d.
Administered Number Compliance
treatment of subjects
Alendronate 10 118 Yes 91 (77.1%)
No 10 (8.5%)
Lost contact for 17 (14.4%)
the last year
Table III. Causes of treatment discontinuation
Tabela III. Przyczyny zaprzestania leczenia
Administered Number Compliance
treatment  of subjects
Alendronate 10 23 Intolerance 11 (47.8%)
BMD 6 (26.1%)
improvement
Concomitant 2 (8.7%)
diseases
Price 1 (4.3%)
Inconvenience 3 (13.1%)
of intake, lack
 of confidence
Table IV. Causes of treatment changes
Tabela IV. Przyczyny zmiany leczenia
Treatment N (132 subjects) Causes
continuation
Alendronate 83 (62.9%)
— the same agent
With various agents 49 (37.1%) Intolerance
Inconvenience of
drug intake
Financial aspects
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6 months 8.5% of patients, discontinued their treatment.
It is worth mentioning that in both periods of observa-
tion (18 or 6 months) almost the same percentage of
people stopped consultations at our Outpatient Clinic
(15.6% and 14.4%, respectively). Telephone interviews
with the patients who stopped attending the Outpa-
tient Clinic revealed that more than 50% of them di-
scontinued the treatment. The results of our paper are
compared to the work of a Canadian group (Table V)
[25]. The Canadian Database of Osteoporosis and Oste-
opaenia (CANDOO), a prospective observational data-
base designed to capture clinical data, was searched for
patients who started therapy with 1,196 initiating eti-
dronate, 477 alendronate therapy for women and men,
and 294 hormone replacement therapy for women.
After 1 year, 90.3% of patients were still taking etidro-
nate compared with 77.6% for daily alendronate and
80.1% of patients on HRT, which decreased to 44.5%
after 6 years. Reginster and Lecart [26] suggest that the
persistence rates in the CANDOO study may be artifi-
cially high. The study took place in a clinic where the
patients initially gave signed consent and were given
verbal encouragement to continue treatment. Our ob-
servations were equally encouraging, bearing in mind
the fact that, contrary to the prospective CANDOO stu-
dy, our data were retrospective.
The results of persistence have not been very opti-
mistic in a number of reports. For example, medication
persistence was only in 39.0% of patients, receiving da-
ily alendronate therapy at month 12 of the study pe-
riod [27]. In a questionnaire study of 219 women with
osteoporosis taking daily risedronate, 1 in 4 did not com-
ply correctly with dosing instructions, despite counsel-
ling [28]. In a subsequent paper, using a telephone in-
terview survey, it was reported that within 13 months
of observation of 812 women with osteoporosis, treated
daily with alendronate, 56% of the patients were non-
compliant [29].
Good adherence to osteoporosis treatment is very
important for its effectiveness. Among the 999 respon-
dents — patients with osteoporosis, the effectiveness
was ranked as the most important determinant of pre-
ference (79%), compared with the time on market (14%),
dosing procedure (4%), and dosing frequency (3%).
Incorporation of patient preferences in the medication
decision-making process could enhance patient com-
pliance and clinical outcomes [30]. This last opinion is
very important because it has been shown that com-
pliance below 66% in drug treatment results in sub-opti-
mal improvement in bone density [20]. On the other
hand, improving compliance in the actual practice may
significantly decrease osteoporosis-related fracture ri-
sks (a 16% lower fracture risk during 2 years) [31]. It has
been observed that the antifracture effectiveness, asso-
ciated with high adherence to oral bisphosphonates,
varied substantially according to age and fracture type
[32]. Caro et al. [33] showed that poorly compliant pa-
tients were significantly more frequently hospitalized
(53.4%), compared to compliant ones (42.6%), leading
to 14% higher costs of medical services.
In our analysis, the main reason for discontinuation
of alendronate treatment was intolerance (especially side
effects from the gastrointestinal tract) (47.8%), health pro-
blems unrelated to osteoporosis (8.7%), inconvenience
with the daily regimen (13.1%), costs (4.3%), and poor
improvement of the clinical condition (26.1%). This is in
agreement with the results of other authors [20, 34].
Among patients completing another study (4,231), the
percentage of patients with high compliance was 80% (Ra-
loxifene), 79% (Alendronate 10), 65% (Alendronate 70) and
76% (Risedronate). The discontinuation, due to side ef-
fects, was highest on alendronate 70 (7.0%), followed by
alendronate 10 (6.4%), raloxifene (3.8%), and risedronate
(3.4%). The discontinuation rate was higher for patients
with a history of surgical menopause, increased age, lack
of knowledge about medical prevention of osteoporosis,
and thin frame as a reason for intervention [35].
Table V. Studies which show the scale of therapy discont-
inuation with bisphosphonates, compared to our results
Tabela V. Częstość zaprzestania leczenia bisfosfonianami
w doniesieniach z badań klinicznych w porównaniu
z rezultatami uzyskanymi przez autorów
Clinical No. of Discontinuation of
Trials subjects therapy (in months)
Lombas [14] 401 ALE 10 51% within 12
70% within 24
Roldan ECMO [39] 1,877 ALE 10 20% within 4
Negri ECMO [16] 2,552 ALE 70 13% within 6
Papadimitropoulos 1,196 ETI 14.5% within 6
CANDOO [25] 19.1% within 12
Papadimitropoulos 477 ALE 10 29.9% within 12
CANDOO [25] 35.8% within 24
Ettinger [29] 812 ALE 10 44% within 13
Ettinger [27] 211,319 ALE 10 39% within 12
Curtis [32] 101,038 Oral bispho- 44% within 12
sphonates 39% within 24
35% within 36
Ringe [35] 452 ALE 10 21% within 12
769 ALE 70 35% within 12
Own data 118 ALE 10 8.5% within 6
on the average
(+14.4%)
64 ALE 10 20.4% within 18
(+15.6%)
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Another observation, made during our study, was
connected with the large number of alendronate gene-
rics in our country. During the time of our observation,
63% of the patients received the same active substance,
whereas in 37% of patients, pharmaceutical generics
were changed due to intolerance, inconvenience, or
cost. In the group of studied patients, some of them re-
quested that the mode of application be changed from
daily to weekly, for their convenience. This is in con-
formity to other results [34]. They have found that the
main reasons for discontinuing therapy with antiresorp-
tive treatment were: side effects (40%), high cost of
medicine (27%), ineffective treatment (17%), patient’s
demands (12%), changing medicines by another doctor
(3%), and therapeutic success (1%). Claxton (36) sugge-
sted that the prescribed number of doses per day is in-
versely related to compliance. Simpler, less frequent
dosing regimens resulted in better compliance across
a variety of therapeutic classes. This is reflected in oste-
oporosis therapy. Postmenopausal women prescribed
a weekly regimen of bisphosphonates had significan-
tly greater rates of compliance than women prescribed
a daily regimen did, and they persisted longer with tre-
atment. However, compliance and persistence rates
were suboptimal for both regimens [18, 37].
Osteoporosis is a chronic disease, which needs long
clinical observation and constant adherence to medica-
tion recommendations. Analyzing our observations and
the results of others, we suggest that the main reasons
for discontinuation of treatment are not only digestive
incidents but also problems with receiving prescriptions
within the first 3 months of treatment, dissatisfaction
with the clinical condition, and bad monitoring. In our
opinion, effective communication and more frequent
follow-up visits would greatly improve the adherence
to osteoporosis treatment modalities. Variations in the
compliance with medical treatment of osteoporosis mi-
ght also depend on other factors: patient beliefs, social
and economic conditions, physical predisposition, or
health problems. Compliance could be improved with
the patient’s preference of treatment regimen. It is of
utmost importance to inform patients about their dia-
gnosis and long-term treatment plan, highlighting the
role of persistence with therapy and compliance with
dosing recommendations [38]. Adherence to drug ad-
ministration regime improves BMD, reduces femoral
neck and spine fracture risks, while also decreasing the
costs of in-house therapy.
Conclusions
The obtained results demonstrate moderate incomplian-
ce to medical recommendations by patients treated for
osteoporosis with alendronate 10. The critical points,
decisive for treatment discontinuation, include thera-
py-induced adverse effects, no continuous contact with
consultant, and no subjective clinical improvement.
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